Advancing Clinical Care and Research with Confidence

Gain tailored insights into cardiovascular
care trends across the nation.

Advancing Clinical Care and Research with Confidence

Gain tailored insights into cardiovascular trends across the nation.

The Challenge

Patient Enrollment Is Time Consuming and Costly

egnite provides a more targeted, efficient way to conduct trials and research:

Find the Right Patients
at the Right Time

Using artificial intelligence and advanced data processing to pre-screen for eligible patients

Streamline Enrollment

Improve efficiencies by up to 55% compared to traditional screening techniques

Discover Key Drivers
of Patient Attrition

Enhance patient and site selection

PARTNERS

The Data

Welcome to One of the Largest Ecosystems of Real-World Cardiovascular Data

0 +
CV ENCOUNTERS
0 +
ECHOCARDIOGRAMS
0 +
SIGNIFICANT CV DISEASE FINDINGS

Longitudinal, echo and EHR data validated by clinicians daily

Leading-edge big data processing techniques scan over 3,000 unique data points per patient, updating data nightly

Proprietary NLP transforms unstructured echo data into usable information

Geographically diverse dataset from across the U.S.

0 +
CV ENCOUNTERS
0 +
ECHOCARDIOGRAMS
0 +
SIGNIFICANT CV DISEASE FINDINGS

Proprietary NLP transforms unstructured echo data into usable information

Geographically diverse dataset from across the U.S.

Longitudinal, echo and EHR data validated by clinicians daily

Leading-edge big data processing techniques scan over 3,000 unique data points per patient, updating data nightly

*Data from egnite’s de-identified database of 26 teaching and non-teaching US institutions with appropriate permissions.

Our Products

egnite Therapy Accelerator

Drive patient activation
for existing therapies
Drive patient activation
for existing therapies
Accelerate enrollment
for clinical trials

egnite Research

Collaborate to answer contemporary questions in cardiovascular disease:

Heart
Failure

Atrial
Fibrillation

Mitral
Regurgitation

Mitral
Stenosis

Tricuspid
Regurgitation

Aortic
Regurgitation

Aortic
Stenosis

Presented or Published In

Testimonials

Leading life sciences organizations partner with egnite to expand the boundaries of research and care.

By utilizing cutting-edge analytics and JenaValve's innovative transcatheter therapies, we hope to drive urgent change, provide improved treatment options, and ultimately save lives. These findings also provide valuable insights for healthcare providers and policymakers, encouraging further attention towards improving outcomes for patients suffering from AR.
Duane Pinto, MD, MPH
Chief Medical Officer
JenaValve
Our goal with the development of the AccuCinch System is to provide a minimally invasive treatment option to further improve the lives of heart failure patients whose symptoms progress despite guideline-directed medical therapy. This partnership with egnite and The Christ Health Network will allow us to deploy A.I. tools such as egnite's Trial Accelerator and expedite identification of eligible candidates for the CORCINCH-HF trial.
Mark Miles, MBA
Chief Commercial Officer
Ancora Heart

Resources

CRF-TCT
Real-World Evidence

Acute Valve Syndrome in Aortic Stenosis

“These findings are extremely important and complementary to the recently presented EARLY TAVR Trial, published in the NEJM. The absence of symptoms was traditionally considered a sign of relative safety. However, this study shows how frequent acute valve syndrome is in patients undergoing AVR, and how patients would benefit greatly from intervention before symptoms appear.” […]

image000002
Press

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR)

egnite Inc.’s Real-World Evidence Demonstrates Improved Survival in Asymptomatic Aortic Stenosis Patients Undergoing Aortic Valve Replacement (AVR) Key Findings Demonstrate 3x Improved Survival for Asymptomatic AS Patients Undergoing AVR versus AS Patients Presenting with Acute Valve Syndrome ALISO VIEJO, Calif. – October 28, 2024 – egnite, Inc., a leading cardiovascular digital health company, today announced the […]

IMG_7272
Press

egnite, Inc. and JenaValve Announce Novel Research on Outcomes with Untreated Aortic Regurgitation at the 2024 American College of Cardiology Conference

egnite, Inc., a leading digital health company specializing in cardiovascular care, today announced the addition of two distinguished physicians, Vinod H. Thourani, MD and Nicholas Amoroso, MD to its Medical Advisory Board. Their wealth of expertise in cardiovascular care and dedication to innovation will significantly contribute to egnite’s mission to improve cardiovascular patient care nationwide.

Connect with egnite.

Schedule my demo today.